Andrew Reardon Ligand Pharmaceuticals Inc (LGND) insider trading activity

LGND Quotes by TradingView

Andrew Reardon is CLO & Secretary of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 31,903 shares of LGND, which is worth approximately $3.63 Million. The most recent transaction as insider was on Jun 23, 2025, when has been sold 500 shares (Common Stock) at a price of $114.08 per share, resulting in proceeds of $57,040. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 31.9K
8.28% 3M change
41.58% 12M change
Total Value Held $3.63 Million

Andrew Reardon Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 23 2025
SELL
Open market or private sale
$57,040 $114.08 p/Share
500 Reduced 1.54%
31,903 Common Stock
Jun 10 2025
SELL
Open market or private sale
$57,270 $114.54 p/Share
500 Reduced 1.52%
32,403 Common Stock
May 15 2025
SELL
Open market or private sale
$104,000 $104.0 p/Share
1,000 Reduced 2.95%
32,903 Common Stock
Mar 04 2025
BUY
Grant, award, or other acquisition
-
6,415 Added 15.57%
34,783 Common Stock
Feb 15 2025
SELL
Payment of exercise price or tax liability
$238,800 $120.0 p/Share
1,990 Reduced 6.56%
28,368 Common Stock
Feb 14 2025
SELL
Payment of exercise price or tax liability
$543,960 $120.0 p/Share
4,533 Reduced 12.99%
30,358 Common Stock
Feb 14 2025
BUY
Grant, award, or other acquisition
-
12,357 Added 27.79%
32,116 Common Stock
Sep 23 2024
SELL
Open market or private sale
$199,200 $99.6 p/Share
2,000 Reduced 8.15%
22,534 Common Stock
Sep 23 2024
BUY
Exercise of conversion of derivative security
$104,540 $52.27 p/Share
2,000 Added 7.54%
24,534 Common Stock
Aug 28 2024
SELL
Open market or private sale
$159,585 $106.39 p/Share
1,500 Reduced 6.24%
22,534 Common Stock
Aug 28 2024
BUY
Exercise of conversion of derivative security
$78,405 $52.27 p/Share
1,500 Added 5.87%
24,034 Common Stock
Aug 10 2024
SELL
Payment of exercise price or tax liability
$89,843 $100.16 p/Share
897 Reduced 3.98%
21,637 Common Stock
Jun 28 2024
BUY
Other acquisition or disposition
$19,973 $60.71 p/Share
329 Added 1.44%
22,534 Common Stock
May 09 2024
SELL
Open market or private sale
$830,400 $83.04 p/Share
10,000 Reduced 31.05%
22,205 Common Stock
May 09 2024
BUY
Exercise of conversion of derivative security
$522,700 $52.27 p/Share
10,000 Added 23.69%
32,205 Common Stock
Feb 27 2024
BUY
Grant, award, or other acquisition
-
7,208 Added 24.51%
22,205 Common Stock
Feb 15 2024
SELL
Payment of exercise price or tax liability
$44,267 $74.65 p/Share
593 Reduced 3.8%
14,997 Common Stock
Dec 29 2023
BUY
Other acquisition or disposition
$10,867 $60.71 p/Share
179 Added 1.14%
15,590 Common Stock
Aug 10 2023
SELL
Payment of exercise price or tax liability
$61,650 $68.73 p/Share
897 Reduced 5.5%
15,411 Common Stock
Mar 24 2023
SELL
Open market or private sale
$20,976 $69.92 p/Share
300 Reduced 1.81%
16,308 Common Stock
Feb 23 2023
BUY
Grant, award, or other acquisition
-
5,668 Added 25.44%
16,608 Common Stock
Nov 30 2022
SELL
Payment of exercise price or tax liability
$78,221 $72.9 p/Share
1,073 Reduced 8.93%
10,940 Common Stock
AR

Andrew Reardon

CLO & Secretary
San Diego, CA

Track Institutional and Insider Activities on LGND

Follow LIGAND PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

News

Receive news related to LIGAND PHARMACEUTICALS INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on LGND